Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

Autor: Leuchte Hanno, Baezner Carlos, Meis Tobias, von Wulffen Werner, Leuschner Stefan, Ihle Franziska, Herrera Vivian A, Huppmann Patrick, Hoffmann Anna L, Neurohr Claus, Baumgartner Rainer, Zimmermann Gregor, Behr Juergen
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: Respiratory Research, Vol 12, Iss 1, p 66 (2011)
Druh dokumentu: article
ISSN: 1465-9921
DOI: 10.1186/1465-9921-12-66
Popis: Abstract Background Lymphangioleiomyomatosis (LAM) is a rare lung disease characterised by progressive airflow obstruction. No effective medical treatment is available but therapy with sirolimus has shown some promise. The aim of this observational study was to evaluate sirolimus in progressive LAM. Methods Sirolimus (trough level 5 - 10 ng/ml) was administered to ten female patients (42.4 ± 11.9 years) with documented progression. Serial pulmonary function tests and six-minute-walk-distance (6-MWD) assessments were performed. Results The mean loss of FEV1 was -2.30 ± 0.52 ml/day before therapy and a significant mean gain of FEV1 of 1.19 ± 0.26 ml/day was detected during treatment (p = 0.001). Mean FEV1 and FVC at baseline were 1.12 ± 0.15 l (36.1 ± 4.5%pred.) and 2.47 ± 0.25 l (69.2 ± 6.5%pred.), respectively. At three and six months during follow-up a significant increase of FEV1 and FVC was demonstrated (3 months ΔFEV1: 220 ± 82 ml, p = 0.024; 6 months ΔFEV1: 345 ± 58 ml, p = 0.001); (3 months ΔFVC: 360 ± 141 ml, p = 0.031; 6 months ΔFVC: 488 ± 138 ml, p = 0.006). Sirolimus was discontinued in 3 patients because of serious recurrent lower respiratory tract infection or sirolimus-induced pneumonitis. No deaths and no pneumothoraces occurred during therapy. Conclusions Our data suggest that sirolimus might be considered as a therapeutic option in rapidly declining LAM patients. However, sirolimus administration may be associated with severe respiratory adverse events requiring treatment cessation in some patients. Moreover, discontinuation of sirolimus is mandatory prior to lung transplantation.
Databáze: Directory of Open Access Journals